Late radiation-related lymphopenia after prostate stereotactic body radiation therapy plus or minus supplemental pelvic irradiation

Autor: Kelly Gaudian, Min Jung Koh, Min Ji Koh, Peter Jermain, Irfan Khan, Diya Kallam, Zach Lee, Ryan R. Collins, Zoya Zwart, Malika Danner, Alan Zwart, Deepak Kumar, Michael B. Atkins, Simeng Suy, Sean P. Collins

Publikováno v: Frontiers in Oncology, Vol 14 (2024)

IntroductionPrior studies suggest lymphopenia following radiation therapy may impact toxicity and cancer control. Chronic radiation-related lymphopenia (RRL) has been noted in prostate cancer patients treated with conventionally fractionated pelvic r

Externí odkaz: https://doaj.org/article/a84efa618455491090554a44fc51390f

Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214

Autor: Thomas Powles, Laurence Albiges, David F McDermott, Michael B Atkins, Toni K Choueiri, Bernard Escudier, Elizabeth R Plimack, Brian I Rini, Martin H Voss, Hans J Hammers, Chung-Han Lee, Robert J Motzer, Yoshihiko Tomita, Nizar M Tannir, Meredith M Regan, Charlene M Mantia, Lisa Rosenblatt, Opeyemi A Jegede

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 12, Iss 7 (2024)

Background Immunotherapy can be associated with prolonged disease control even after cessation of treatment without the need for further cancer-directed therapy. Treatment-related adverse events (TRAEs) can also persist after discontinuation of thera

Externí odkaz: https://doaj.org/article/e929a9c890ec467cac7b04eb3f99fada

Multi-omic profiling reveals discrepant immunogenic properties and a unique tumor microenvironment among melanoma brain metastases

Autor: Gino K. In, Jennifer R. Ribeiro, Jun Yin, Joanne Xiu, Matias A. Bustos, Fumito Ito, Frances Chow, Gabriel Zada, Lindsay Hwang, April K. S. Salama, Soo J. Park, Justin C. Moser, Sourat Darabi, Evidio Domingo-Musibay, Maria L. Ascierto, Kim Margolin, Jose Lutzky, Geoffrey T. Gibney, Michael B. Atkins, Benjamin Izar, Dave S. B. Hoon, Ari M. VanderWalde

Publikováno v: npj Precision Oncology, Vol 7, Iss 1, Pp 1-10 (2023)

Abstract Melanoma brain metastases (MBM) are clinically challenging to treat and exhibit variable responses to immune checkpoint therapies. Prior research suggests that MBM exhibit poor tumor immune responses and are enriched in oxidative phosphoryla

Externí odkaz: https://doaj.org/article/32efd05519e741b4bbdba359b3adab39

Re: Michael B. Atkins, Elizabeth R. Plimack, Igor Puzanov, et al. Axitinib in Combination with Pembrolizumab in Patients with Advanced Renal Cell Cancer: A Non-randomised, Open-label, Dose-finding, and Dose-expansion Phase 1b Trial. Lancet Oncol 2018;19:405-15.

Autor: Di Nunno V; Division of Oncology, S. Orsola-Malpighi Hospital, Bologna, Italy., Santoni M; Oncology Unit, Macerata Hospital, Macerata, Italy., Massari F; Division of Oncology, S. Orsola-Malpighi Hospital, Bologna, Italy. Electronic address: fmassari79@gmail.com.

Publikováno v: European urology [Eur Urol] 2018 Aug; Vol. 74 (2), pp. e50. Date of Electronic Publication: 2018 Apr 27.

1317 Enhancing patient safety in melanoma treatment: harnessing machine learning for predicting immune-related adverse events

Autor: Samir Gupta, Michael B Atkins, Neil J Shah, Jacob Zaemes, Shaked Lev Ari, Yili Zhang, Adil Alaoui, Subha Madhavan, Peter McGarvey

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)

Externí odkaz: https://doaj.org/article/a4c1b501eb1d4b51a05770744fdfed2a